MedTrace Logo

Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer

NCT04927910 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-04-26

No results posted yet for this study

Summary

This study aims to evaluate the feasibility, acceptability and preliminary effects of self-applied acupressure on arthralgia-fatigue-sleep disturbance symptom cluster in breast cancer survivors receiving aromatase inhibitors. This is a preliminary randomized controlled trial, with a three-arm trial design including verum self-acupressure, sham self-acupressure, and usual care. Subjects will include 52 breast cancer survivors who are receiving aromatase inhibitors and have experienced a moderate level of joint pain and at least one of the two symptoms including fatigue and sleep disturbance. Subjects who are randomized to either the verum self-acupressure group (group A) or the sham self-acupressure group (group B) will receive up to 8 weeks of the intervention consisting of two components: (1) two individual/group acupressure training sessions over 2 weeks and (2) self-acupressure for 6 weeks. The method and duration of self-acupressure in the sham group will be the same to those in the verum intervention group. The control group will receive usual care. The outcome measures of this study will be related to feasibility, acceptability and preliminary effects of self-acupressure. Individual in-depth interviews will be conducted with selected participants in group A and B to understand their perceptions and perceived effectiveness of the intervention.

Conditions

  • Breast Neoplasms
  • Cancer Survivor

Interventions

OTHER

Ture self-acupressure

8-week intervention of self-acupressure on acupoints

OTHER

Sham self-acupressure

8-week intervention of self-acupressure on non-acupoints

OTHER

Usual care

routine care by hospitals

Sponsors & Collaborators

  • The Huazhong University of Science and Technology Union Shenzhen Hospital

    collaborator UNKNOWN

  • The Hong Kong Polytechnic University

    lead OTHER

Principal Investigators

  • Huilin Cheng, PhD · The Hong Kong Polytechnic University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-05
Primary Completion
2022-01-29
Completion
2022-03-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927910 on ClinicalTrials.gov